IPM Take
This is the clearest obesity-access lesson in Europe right now: a positive HTA recommendation does not mean immediate population access. Tirzepatide may be clinically and cost-effective for a large eligible group, but NHS England is phasing access because primary care capacity, workforce, funding and wrap-around support are not unlimited. The political issue is not whether obesity pharmacotherapy works. It is whether health systems can prioritise fairly while building the pathway they should already have had.
Executive Summary
NICE recommends tirzepatide, Mounjaro, for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity, only if they have an initial BMI of at least 35 kg/m² and at least one weight-related comorbidity, with lower BMI thresholds for people from some ethnic backgrounds. NHS England’s interim commissioning guidance states that around 3.4 million people could be eligible under the NICE appraisal, but access in primary care will be phased. The first three years are expected to reach around 220,000 people, with primary care access prioritised by BMI and qualifying comorbidities.
Why it matters
- HTA bodies: Need to consider whether positive recommendations are deliverable when the eligible population is large and service models are not yet ready.
- Payers / public authorities: Must manage affordability, workforce capacity, wrap-around care and fair prioritisation during phased access.
- Patients / advocates: Should track whether phased rollout reduces inequity or creates a long queue where private access moves faster than NHS access.
Before this rollout, obesity drug access was often framed as a binary question: approved or not approved, reimbursed or not reimbursed. Tirzepatide shows that the real situation is messier.
What changed is that England now has a recommended obesity medicine with a defined NHS implementation pathway. Specialist weight management services can provide access to eligible patients, while primary care access is being phased because the system needs time to build capacity, service models and wrap-around support.
In year one, primary care prioritisation focuses on people with BMI 40 kg/m² or higher and at least four qualifying comorbidities: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. In later years, primary care access expands to additional cohorts based on BMI and number of qualifying comorbidities.
The implication is direct. Obesity care is becoming personalised by risk, comorbidity and system capacity, not only by BMI. But phased access also creates a fairness problem. If millions are eligible and only a fraction can receive treatment early, the system must be transparent about prioritisation, follow-up and how quickly access will expand.
